Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 12/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29565050 | 0.90 | HPGD (0.40) | HPGDP2RX7GPR119KDM4E | |
| SCHEMBL23680668 | 0.90 | HPGD (0.40) | HPGDP2RX7GPR119KDM4E | |
| SCHEMBL23680764 | 0.82 | HPGD (0.48) | HPGDP2RX7KDM4ESLC6A7 | |
| SCHEMBL23680574 | 0.80 | HPGD (0.50) | HPGDP2RX7GPR119KDM4ESLC6A7 | |
| SCHEMBL23680598 | 0.79 | HPGD (0.39) | HPGDP2RX7GPR119KDM4E | |
| SCHEMBL23675254 | 0.73 | HPGD (0.53) | HPGDP2RX7GPR119KDM4ESLC6A7 | |
| SCHEMBL23680834 | 0.69 | CNR2 (0.41) | HPGD | |
| SCHEMBL23680552 | 0.69 | HPGD (0.78) | HPGDKDM4ESLC6A7 | |
| SCHEMBL23680595 | 0.69 | HPGD (0.54) | HPGDGPR119KDM4ESLC6A7 | |
| SCHEMBL23680594 | 0.66 | HPGD (0.43) | HPGDGPR119KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345702-B1 | PGDH inhibitors and methods of making and using | MYOFORTE THERAPEUTICS, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2022082009-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | EPIRIUM BIO INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2021151014-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | MYOFORTE THERAPEUTICS, INC. (US) | 2021-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345702-B1 | PGDH inhibitors and methods of making and using | HPGD, HPGDS, PTGS1 | HPGD 1/4885P2RX7 3611/4885GPR119 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.